Zika virus is transmitted through Aedes mosquito bite, which can also transmit chikungunya, dengue, and yellow fever. The other modes of transmission of Zika virus is through sex and from an infected mother to the fetus. The onset of Zika virus is yet not clear. The symptoms are similar to that of dengue, including fever, skin rashes, joint pain, and headache, which are mild and last for two to seven days. Research Beam Model: Research Beam Product ID: 1068868 5370 USD New
Zika Virus Vaccines Market by Forecast Scenario Analysis (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2017-2022
 

Zika Virus Vaccines Market by Forecast Scenario Analysis (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2017-2022

Zika Virus Vaccines Market by Forecast Scenario Analysis (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportuni

Category : Pharmaceuticals
Published On : January  2017
Pages : 97

request-discount


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

Zika virus is transmitted through Aedes mosquito bite, which can also transmit chikungunya, dengue, and yellow fever. The other modes of transmission of Zika virus is through sex and from an infected mother to the fetus. The onset of Zika virus is yet not clear. The symptoms are similar to that of dengue, including fever, skin rashes, joint pain, and headache, which are mild and last for two to seven days.

The Zika virus vaccines market is estimated to generate $14,500 million in 2017, and is expected to reach $18,697 million by 2022, growing at a CAGR of 5.2%. The market has high potential owing to increase in demand for vaccines for immunization and further prevention in regions such as Latin America and Central America. According to WHO, approximately 1.6 million individuals are infected with Zika virus, and the number is exponentially increasing. In addition, surgical demand for vaccines that can cure Zika-linked birth defects has increased.

Zika virus disease is caused by mosquitoes that belongs to Flavivirus genus, and was first identified in Uganda in 1947 in monkeys. It was later identified in humans in 1952 in Uganda and the United Republic of Tanzania. Major outbreak of the disease was reported in 2007 in the Yap Island. In addition, an association between Zika virus infection and Guillain–Barré syndrome was reported in July 2015 in Brazil, and later in October 2015, Brazil reported an association between Zika virus infection and microcephaly.

The global Zika virus vaccine market is segmented based on forecast scenario analysis and geography. On the basis of forecast scenario analysis, the market is categorized into rapid growth, moderate growth, and low growth. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS:

  • In-depth study of the global Zika virus vaccines market was conducted based on the current disease prevalence, target population, and pricing to generate market size & forecast from 2017 to 2022.
  • Potential analysis of opportunities was evaluated to understand different aspects of Zika virus vaccines that are currently clinical trials along with the variants that are expected to gain prominence in the future.
  • Key market players are profiled and their strategies are analyzed thoroughly to understand the various technologies adopted by them to manufacture Zika virus vaccines.

KEY MARKET SEGMENT:

By Forecast Scenario Analysis

  • Rapid Growth Scenario
  • Moderate Growth Scenario
  • Low Growth Scenario

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

By Country

  • Brazil
  • Mexico
  • Philippines
  • Vietnam
  • Thailand
  • Rest of the World

KEY PLAYERS

  • Immunovaccine Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Bharat Biotech International Ltd.
  • NewLink Genetics Co.
  • Inovio Pharmaceuticals, Inc.
  • GeneOne Life Science Inc.
  • GlaxoSmithKline Plc.
  • Sanofi S.A.
  • Hawaii Biotech Inc.

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
1.4.4. Assumptions for growth scenarios
1.4.5. Expected pricing per dose for Zika virus vaccine

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. TOP INVESTMENT POCKETS
3.3. ZIKA VIRUS-KEY FACTS

3.3.1. Mode of infection and transmission of Zika virus

3.3.1.1. From infected mother to child
3.3.1.2. Through sex
3.3.1.3. Through blood transfusion
3.3.1.4. Through laboratory and healthcare setting exposure

3.3.2. Signs and symptoms of infection
3.3.3. Prevention and control of Zika virus

3.3.3.1. Vector control options

3.3.3.1.1. Targeted residual spraying
3.3.3.1.2. Space spraying

3.3.3.2. Personal protection measures

3.3.4. Prevalence and incidence
3.3.5. Diagnosis and treatment of Zika virus

3.3.5.1. Trioplex real-time RT-PCR assay
3.3.5.2. Zika MAC-ELISA

3.4. REGULATION OF VACCINES BY FDA

3.4.1. Licensure of vaccines in U.S.
3.4.2. Priority Review Voucher System
3.4.3. U.S. licensed flavivirus vaccines

3.5. CLINICAL TRIALS
3.6. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
3.7. MARKET OPPORTUNITIES

3.7.1. Surging need for medical solutions for the prevention & treatment of Zika-linked birth defects
3.7.2. High rate of incidence of active Zika virus infection

Chapter: 4 FORECAST SCENARIO ANALYSIS OF ZIKA VIRUS VACCINES

4.1. OVERVIEW

4.1.1. Market size and forecast

4.1.1.1. Rapid growth scenario
4.1.1.2. Moderate growth scenario
4.1.1.3. Low growth scenario

Chapter: 5 POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINE MARKET, BY GEOGRAPHY

5.1. INTRODUCTION
5.2. NORTH AMERICA

5.2.1. Market size and forecast

5.3. EUROPE

5.3.1. Market size and forecast

5.4. ASIA-PACIFIC

5.4.1. Market size and forecast

5.5. LAMEA

5.5.1. Market size and forecast

Chapter: 6 POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES-BY COUNTRY

6.1. BRAZIL

6.1.1. Market size and forecast

6.2. MEXICO

6.2.1. Market size and forecast

6.3. PHILIPPINES

6.3.1. Market size and forecast

6.4. VIETNAM

6.4.1. Market size and forecast

6.5. THAILAND

6.5.1. Market size and forecast

6.6. REST OF THE WORLD

6.6.1. Market size and forecast

Chapter: 7 COMPANY PROFILES

7.1. BHARAT BIOTECH INTERNATIONAL LTD

7.1.1. Company overview
7.1.2. Company Snapshot
7.1.3. Operating business segments
7.1.4. Product pipeline
7.1.5. Research funding
7.1.6. Key strategic developments

7.2. GENEONE LIFE SCIENCE, INC.

7.2.1. Company overview
7.2.2. Company Snapshot
7.2.3. Operating business segments
7.2.4. Product pipeline
7.2.5. Key strategic developments

7.3. GLAXOSMITHKLINE PLC

7.3.1. Company overview
7.3.2. Company Snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic developments

7.4. HAWAII BIOTECH INC

7.4.1. Company overview
7.4.2. Key strategic developments
7.4.3. Company Snapshot
7.4.4. Operating business segments

7.5. IMMUNOVACCINE INC.

7.5.1. Company overview
7.5.2. Company Snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Product pipeline
7.5.6. Key strategic developments

7.6. INOVIO PHARMACEUTICALS, INC

7.6.1. Company overview
7.6.2. Company Snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Product pipeline
7.6.6. Research funding
7.6.7. Key strategic developments

7.7. NEWLINK GENETICS CORPORATION

7.7.1. Company overview
7.7.2. Company Snapshot
7.7.3. Business performance
7.7.4. Product pipeline

7.8. SANOFI S.A.

7.8.1. Company overview
7.8.2. Company Snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Product pipeline
7.8.6. Research funding
7.8.7. Key strategic developments

7.9. TAKEDA PHARMACEUTICAL CO., LTD.

7.9.1. Company overview
7.9.2. Company Snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Product pipeline
7.9.6. Research funding

LIST OF TABLES

TABLE 1. RAPID GROWTH SCENARIO OF POTENTIAL ZIKA VIRUS VACCINES MARKET, BY GEOGRAPHY, 2017-2022 ($MILLION)
TABLE 2. MODERATE GROWTH SCENARIO OF POTENTIAL ZIKA VIRUS VACCINES MARKET, BY GEOGRAPHY, 2017-2022 ($MILLION)
TABLE 3. LOW GROWTH SCENARIO OF POTENTIAL ZIKA VIRUS VACCINES MARKET, BY GEOGRAPHY, 2017-2022 ($MILLION)
TABLE 4. NORTH AMERICA: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 5. EUROPE: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 6. ASIA-PACIFIC: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 7. LAMEA: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 8. BRAZIL: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 9. MEXICO: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 10. PHILIPPINES: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 11. VIETNAM: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 12. THAILAND: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 13. REST OF THE WORLD: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
TABLE 14. BHARAT BIOTECH INTERNATIONAL LIMITED: COMPANY SNAPSHOT
TABLE 15. BHARAT BIOTECH INTERNATIONAL LIMITED: OPERATING SEGMENTS
TABLE 16. GENEONE LIFE SCIENCE INC.: COMPANY SNAPSHOT
TABLE 17. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 18. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 19. HAWAII BIOTECH INC.: COMPANY SNAPSHOT
TABLE 20. HAWAII BIOTECH INC.: OPERATING SEGMENTS
TABLE 21. IMMUNOVACCINE INC.: COMPANY SNAPSHOT
TABLE 22. INOVIO PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 23. NEWLINK GENETICS: COMPANY SNAPSHOT
TABLE 24. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 25. SANOFI S.A.: OPERATING SEGMENTS
TABLE 26. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 27. TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. ZIKA VIRUS VACCINES MARKET SEGMENTATION
FIGURE 2. NUMBER OF COUNTRIES AND TERRITORIES REPORTING MOSQUITO-BORNE ZIKA VIRUS TRANSMISSION AS OF OCTOBER 27, 2016, BY REGION
FIGURE 3. RISK OF ZIKA VIRUS INFECTION DUE TO TRAVELERS FROM BRAZIL TO SPECIFIC COUNTRIES
FIGURE 4. FLOWCHART OF VACCINE APPROVAL
FIGURE 5. NUMBER OF ZIKA VIRUS INFECTION CASES IN LATIN AMERICA BY COUNTRY
FIGURE 6. NUMBER OF COUNTRIES & TERRITORIES REPORTING MOSQUITO-BORNE ZIKA VIRUS INFECTION BY REGION
FIGURE 7. TIMELINE OF SPREAD FOR ZIKA VIRUS
FIGURE 8. NUMBER OF LABORATORY-CONFIRMED ZIKA VIRUS INFECTION CASES IN U.S., AS OF NOVEMBER 2016
FIGURE 9. REPORTED TRAVEL-ASSOCIATED CASES OF ZIKA VIRUS IN BRITISH POPULATION, BY COUNTRY
FIGURE 10. GLAXOSMITHKLINE PLC.: REVENUE ($MILLION), 2013-2015
FIGURE 11. GLAXOSMITHKLINE PLC.: BY PRINCIPLE PRODUCT CATEGORY, 2015%
FIGURE 12. GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 13. IMMUNOVACCINE INC.: REVENUE ($MILLION), 2013-2015
FIGURE 14. INOVIO PHARMACEUTICALS, INC.: REVENUE ($MILLION), 2013-2015
FIGURE 15. NEWLINK GENETICS: REVENUE ($MILLION), 2013-2015 85
FIGURE 16. SANOFI S.A.: REVENUE ($MILLION), 2013-2015
FIGURE 17. SANOFI S.A.: BY PRINCIPLE PRODUCT CATEGORY, 2015%
FIGURE 18. SANOFI S.A.: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 19. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE ($MILLION), 2013-2015

Enquiry Before Buy